Company Sector
Exosomes
Exosomes includes companies exploring extracellular vesicles as a therapeutic delivery or regenerative medicine platform. It is still an emerging category, but it attracts attention because of its potential use in targeted delivery, tissue repair, and cell-free biologic approaches.
Why watch Exosomes
This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.
Latest Exosomes news
The latest feed items from companies currently grouped under Exosomes.
- 01
CAPRCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
Source: Capricor Therapeutics
- 02
CAPRThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Source: Capricor Therapeutics
- 03
CAPRCapricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Source: Capricor Therapeutics
- 04
- 05
- 06
CAPRCapricor Therapeutics to Present at Upcoming Investor Conferences
Source: Capricor Therapeutics
- 07
CAPRCapricor Therapeutics Expands Commercial Leadership Team
Source: Capricor Therapeutics
- 08
CAPRCapricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Capricor Therapeutics
- 09
CAPRCapricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
Source: Capricor Therapeutics
- 10
- 11
- 12
CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Source: Capricor Therapeutics
- 13
- 14
CAPRCapricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Source: Capricor Therapeutics
- 15
- 16
CAPRCapricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Source: Capricor Therapeutics
- 17
CAPRCapricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Source: Capricor Therapeutics
- 18
- 19
CAPRCapricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Source: Capricor Therapeutics
Companies in Exosomes
1 company tagged with Exosomes.
Frequently Asked Questions
What does the Exosomes sector include?
Exosomes includes companies exploring extracellular vesicles as a therapeutic delivery or regenerative medicine platform. It is still an emerging category, but it attracts attention because of its potential use in targeted delivery, tissue repair, and cell-free biologic approaches.
How many companies are currently tagged with Exosomes?
1 company are currently grouped under Exosomes on BioPharmSignal.
Which companies are most visible in the Exosomes group right now?
CAPR are among the companies currently shown on this sector page.
How can I watch news for Exosomes?
Use the Watch button on this page to subscribe to Exosomes headlines and related company updates through your BioPharmSignal saved filters.
What kinds of updates usually appear for Exosomes?
The livefeed typically surfaces company press releases, clinical readouts, FDA and regulatory updates, partnerships, financings, and commercialization developments tied to companies in Exosomes.